Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies
- Written by ACN Newswire
TOKYO, Nov 30, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Wren Therapeutics Ltd. today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target alpha-synuclein for the potential treatment of synucleinopathies including Parkinson's disease and...